BACKGROUND: In this study, using a murine model of aortic allotransplantation, the role of blockade of signaling through CD28/B7 and CD40/CD40 ligand costimulatory pathways in the evolvement of posttransplant vasculopathy was examined. METHODS: Aortic allografts were transplanted across C57BL/1OJ (H2b)-->C3H (H2k) strain combinations. Transient or more stable blockade of second signaling was achieved by either a single injection or multiple injections of CTLA4-Ig fusion protein (200 microg/dose i.p.) and/or anti-CD40 ligand (CD40L) monoclonal antibody (250 microg i.m.). At day 30 after transplantation, the grafts were harvested for histopathological and immunohistochemical examination. RESULTS: Similar to allografts of untreated animals, aortic allografts obtained from recipients treated with either CTLA4-Ig or anti-CD40L monoclonal antibody alone exhibited marked narrowing of the lumen primarily due to concentric intimal thickening caused by proliferation of alpha-smooth muscle actin-positive cells. Contemporaneous treatment, however, with either a single injection or multiple injections of CTLA4-Ig and anti-CD40L monoclonal antibody resulted in marked diminution of intimal thickening. Interestingly, concurrent prolonged inhibition of CD28/B7 and CD40/CD40L pathways resulted in complete abrogation of the development of posttransplant arteriopathy. CONCLUSION: These data suggest that a more stable disruption of signaling through costimulatory pathways may be required to obviate the development of posttransplant vasculopathy.
BACKGROUND: In this study, using a murine model of aortic allotransplantation, the role of blockade of signaling through CD28/B7 and CD40/CD40 ligand costimulatory pathways in the evolvement of posttransplant vasculopathy was examined. METHODS: Aortic allografts were transplanted across C57BL/1OJ (H2b)-->C3H (H2k) strain combinations. Transient or more stable blockade of second signaling was achieved by either a single injection or multiple injections of CTLA4-Ig fusion protein (200 microg/dose i.p.) and/or anti-CD40 ligand (CD40L) monoclonal antibody (250 microg i.m.). At day 30 after transplantation, the grafts were harvested for histopathological and immunohistochemical examination. RESULTS: Similar to allografts of untreated animals, aortic allografts obtained from recipients treated with either CTLA4-Ig or anti-CD40L monoclonal antibody alone exhibited marked narrowing of the lumen primarily due to concentric intimal thickening caused by proliferation of alpha-smooth muscle actin-positive cells. Contemporaneous treatment, however, with either a single injection or multiple injections of CTLA4-Ig and anti-CD40L monoclonal antibody resulted in marked diminution of intimal thickening. Interestingly, concurrent prolonged inhibition of CD28/B7 and CD40/CD40L pathways resulted in complete abrogation of the development of posttransplant arteriopathy. CONCLUSION: These data suggest that a more stable disruption of signaling through costimulatory pathways may be required to obviate the development of posttransplant vasculopathy.
Authors: C P Larsen; E T Elwood; D Z Alexander; S C Ritchie; R Hendrix; C Tucker-Burden; H R Cho; A Aruffo; D Hollenbaugh; P S Linsley; K J Winn; T C Pearson Journal: Nature Date: 1996-05-30 Impact factor: 49.962
Authors: H Azuma; A Chandraker; K Nadeau; W W Hancock; C B Carpenter; N L Tilney; M H Sayegh Journal: Proc Natl Acad Sci U S A Date: 1996-10-29 Impact factor: 11.205
Authors: R J Armitage; W C Fanslow; L Strockbine; T A Sato; K N Clifford; B M Macduff; D M Anderson; S D Gimpel; T Davis-Smith; C R Maliszewski Journal: Nature Date: 1992-05-07 Impact factor: 49.962
Authors: M E Russell; W W Hancock; E Akalin; A F Wallace; T Glysing-Jensen; T A Willett; M H Sayegh Journal: J Clin Invest Date: 1996-02-01 Impact factor: 14.808
Authors: M H Sayegh; E Akalin; W W Hancock; M E Russell; C B Carpenter; P S Linsley; L A Turka Journal: J Exp Med Date: 1995-05-01 Impact factor: 14.307
Authors: J L Tang; A Aitouche; V Subbotin; A Salam; H Sun; C Gandhi; L A Valdivia; J J Fung; T E Starzl; A S Rao Journal: Transplant Proc Date: 1999 Feb-Mar Impact factor: 1.066
Authors: J Vermeiren; J L Ceuppens; H Haegel-Kronenberger; M De Boer; L Boon; S W Van Gool Journal: Clin Exp Immunol Date: 2004-02 Impact factor: 4.330
Authors: V Subbotin; H Sun; A Aitouche; A Salam; L A Valdivia; J J Fung; T E Starzl; A S Rao Journal: Transplantation Date: 1999-05-27 Impact factor: 4.939
Authors: Vinay P Rao; Stefano E Branzoli; Davide Ricci; Naoto Miyagi; Timothy O'Brien; Henry D Tazelaar; Stephen J Russell; Christopher G A McGregor Journal: J Heart Lung Transplant Date: 2007-12 Impact factor: 10.247
Authors: Amit K Mittal; Nagendra K Chaturvedi; Rae A Rohlfsen; Payal Gupta; Avadhut D Joshi; Ganapati V Hegde; R Gregory Bociek; Shantaram S Joshi Journal: PLoS One Date: 2013-08-01 Impact factor: 3.240